A Phase 2 Study of ASONEP™ to Treat Unresectable and Refractory Renal Cell Carcinoma
Status:
Terminated
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
This Phase 2a study will investigate the efficacy, safety and tolerability of ASONEP™
(sonepcizumab/LT1009) when administered intravenously once a week, every 4 weeks (or cycle),
to subjects with refractory renal cell carcinoma (RCC) until the disease progresses. Subjects
who have failed 3 prior treatments for RCC including vascular endothelial growth factor
(VEGF) and/or mammalian target of rapamycin (mTOR) inhibitors or who have tumors that cannot
be surgically removed will be eligible for screening.